Kick-off meeting of MAGNIFICAT, the new CoEHAR project
This study, strongly advocated by Prof. Riccardo Polosa, aims to investigate the consequences of the combined use of conventional cigarettes and electronic cigarettes on human health.
This study, strongly advocated by Prof. Riccardo Polosa, aims to investigate the consequences of the combined use of conventional cigarettes and electronic cigarettes on human health.
The study found that the antismoking medication varenicline can increase rates of smoking abstinence without causing serious adverse events.
In their work “Respiratory health effects of e-cigarette substitution for tobacco cigarettes: a systematic review”, researchers analyzed 16 studies from 20 publications: most of the studies showed no difference in respiratory parameters. This indicates that electronic nicotine delivery systems substitution for smoking likely does not result in additional harm to respiratory health.
Two CoEHAR researchers will be part of this great event: The CoEHAR Director, Giovanni Li Volti, who is also PI of the replica project, will discuss the latest results of the Replica project and the IN silicon Science Pi, Dr. Renée O’Leary, will present her latest work.
Replica researchers performed a standard toxicology battery of three assays used for product assessment and regulatory applications.
The DiaSmokeFree Working Group send a letter to the American Diabetes Association (ADA) expressing concern and seeking correction of a couple of statements in the ADA guidelines regarding the use…
Professor Li Volti talked about the Replica project results with a presentation titled "The impact of cigarette smoke and reduced risk products aerosol on endothelial function: the REPLICA project"
As requested by experts in the letter: "Our hope is that, in light of scientific evidence, the FCTC and the European Union conduct a careful, balanced, and transparent review of the available scientific evidence regarding non-combustible products, compared to conventional cigarettes, to provide indispensable information for making decisions in the interest of millions of smokers."
At 11.15 am, October 19, prof. Polosa will host remotely the panel Longer Term Outcomes of Cessation and Harm Reduction with a presentation on "Changes in Health Symptoms - Results and Analysis Methodologies".
On behalf of CoEHAR, the Center of Excellence for the acceleration of Harm Reduction, Dr. Lia Emma, researcher of the Replica project, will attend the conference to present the abstract "Cytotoxicity evaluation of vanillin in electronic cigarette liquids on human aortic artery endothelial cells”.